Radient Pharmaceuticals Corporation fka RXPC

[dcspka]

Living, for your information.

"All data to date suggests Minomic's MiStat™ test - a blood or urine test for the proprietary MIL-38 biomarker found on prostate cancer cells - is almost twice as specific as the PSA (Prostate Specific Antigen) diagnostic technology, which is the current gold standard globally. PSA has been controversial, largely due to the high number of false positive results delivered. Current PSA tests have a 40% specificity; MiStat™ has a demonstrated specificity of 76%."

And there you have it. Goldseeker needs to modify his claims for the sake of accuracy.